icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
Digital Experience
AASLD
November 13 - 16 - 2020
Back grey_arrow_rt.gif
 
 
 
LIVER-DIRECTED TARGETING OF PD-L1 WITH RO7191863, A LOCKED NUCLEIC ACID, IN CHRONIC HEPATITIS B: FIRST REPORT OF PHASE 1 TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS
 
 
  AASLD: THE PHARMACOKINETIC AND SAFETY PROFILES OF RO7445482 siRNA [RG6346] ARE SIMILAR BETWEEN ASIAN AND NON-ASIAN HEALTHY VOLUNTEERS AND CHRONIC HEPATITIS B PATIENTS IN A PHASE 1 STUDY (12/13/21)
 
AASLD 2021 Nov 12-15
 
Anna Maria Geretti,1 Edward Gane,2 Karine Lacombe,3 Rozalina Balabanska,4 Gemma Attley,5 Priscila Teixeira,1 Souphalone Luangsay,1 Miriam Triyatni,1 Sijie Lu,6 Spiky Lin,6 Man-Fung Yuen,7 on behalf of the NP40479 Study Group
 
Roche Innovation Center, Basel, Switzerland; 2Auckland Clinical Studies, Auckland, New Zealand; 3 Saint Antoine Hospital, Paris, France; 4 Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria; 5Roche Innovation Center, New York, USA; 6Roche Innovation Center, Shanghai, China; 7Queen Mary Hospital, Hong Kong

1228211

1228212

1228213

1228214

1228215

1228216

1228217